GENELUX CORPORATION BOARD OF DIRECTORS
James L. Tyree, Chairman
James L. Tyree has achieved a distinguished career in health care spanning more than thirty years. His accomplishments are well recognized as an investor, operating executive, and entrepreneur. During the last fourteen years, he has held numerous executive positions at Abbott including Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development, Senior Vice President Global Nutrition, and Executive Vice President Global Pharmaceuticals. He retired as President Abbott Biotechnology Ventures. In his last three positions prior to retirement, Mr. Tyree reported to the Chairman and Chief Executive Officer.
Prior to joining Abbott, Mr. Tyree was the President of Sugen Inc., a biotechnology company focused in oncology. Mr. Tyree led the company’s initial public offering in 1994 and subsequently shaped the company to make it an attractive acquisition target. The company was acquired by Pharmacia in 1997. Earlier in his career, Mr. Tyree held management positions in Bristol-Myers Squibb, Pfizer, and Abbott. Over his entire career, he is a four time expatriate living and working six and a half years in Latin America and seven years in Japan.
Mr. Tyree is a member of the Advisory Board of the University Of Chicago Graduate School Of Business (Booth). He is also a member of the Chicago Council on Global Affairs and co-chairman of the Global Health Policy Roundtable. He is past chairman of the Board of Directors of the Illinois Biotechnology Industry Organization. Mr. Tyree is an Independent Director for SonarMed, a privately held developer and manufacturer of critical care respiratory monitoring technologies. Mr. Tyree joined the Genelux Corporation Board of Directors in May, 2012.
Mr. Tyree earned bachelor degrees in psychology and forensic studies, and a master’s degree in Business Administration from Indiana University.
John Thomas, MA, MBA, PhD
Dr. Thomas served as the company’s first Chief Financial Officer before leaving the post in 2004. He has been a member of the Board of Directors since August 2002. He is currently Dean of the School of Business and Management at La Sierra University in Riverside, California, where he teaches finance, economics and entrepreneurship, a position he has occupied since July 1988. Dr. Thomas holds MBA degrees in finance and marketing, an MA in political economy and a PhD in economics and politics. He has received numerous awards honoring his success as a passionate teacher who motivates students to seek and achieve excellence, among them the Freedom Foundation’s Leavey Award for Excellence in Private Enterprise Education (1998), the Zapara Award to Teaching Excellence (1996) and the Riverside Chambers of Commerce Hero Award for Community Leadership (1995).
Ronald Roy A. Simus
Dr. Ronald Roy A. Simus joined Genelux Corporation as the Company’s first investor in 2002 when the Company was first attempting to build its initial scientific discoveries into a biomedical research and development company. Since this time, Dr. Simus has been involved with the growth and evolution of the Company, including participating in the Company’s management, corporate strategy, fundraising and operations. Today, he serves as the Company’s Interim Secretary, its Vice President of Investor Relations and Investments and is also a member of the Company’s Board of Directors. Dr. Simus holds a DDS and an MS in orthodontics and dentofacial orthopedics from Loma Linda University.
Thomas Zindrick, JD
Tom Zindrick, an experienced life sciences and biotechnology executive with a career spanning more than 20 years, joined Genelux Corporation as President and CEO in May 2014. Mr. Zindrick retired from Amgen Inc in 2009 after a distinguished 16 year career, and has since served as CEO of Amitech Therapeutic Solutions, Inc., a La Jolla, California based discovery and drug development company focused on commercializing allosteric kinase inhibitors, as well independent consultant to Genelux Corporation.
During his career at Amgen, he held positions of increasing responsibility, including Vice President, Associate General Counsel, and Chief Compliance Officer. As Vice President, Associate General Counsel, Mr. Zindrick led intellectual property, licensing and regulatory law teams, and served on cross-functional business and product development teams. These teams were responsible for acquisitions totaling over twenty billion dollars and the licensing and development of six therapeutic products and numerous clinical candidates. As Chief Compliance Officer, he reported to the Board of Directors and led the Corporate Compliance Program, which oversaw the compliance activities of numerous company functions including product development, manufacturing and marketing. Prior to joining Amgen, Mr. Zindrick was an attorney at The Dow Chemical Company.
Mr. Zindrick received his J.D. from the University of Illinois College of Law and a BA in Biology from North Central College in Naperville, Illinois.
Billy J. Parrott
Billy Parrott’s long and illustrious career in advertising, marketing, writing and directing began as a mail boy at McCann Erickson Advertising. In less than 6 years he ultimately rose to Creative Supervisor at Benton & Bowles, responsible for the creative output of over 25% the firm’s billings and winning every copy-writing award in advertising on premier advertising accounts as Crest Toothpaste, Scope Mouth Wash, Hilton Hotels, Oreo, Premium Saltine Crackers, Ritz Crackers, Chips Ahoy, Nestea, Vanquish Headache Remedy and Coca Cola.
His marketing career included consulting for TIME magazine, where Mr. Parrott developed the innovative, groundbreaking and high revenue generating “magazine within the magazine” concept that is still a highly effective marketing tool for the print media. He was also a marketing consultant to AT&T, Roche Pharmaceuticals, Sharp Electronics, JVC, Becton Dichinson, Mead Johnson and others.
Mr. Parrott was CEO & Co-founder of Private Networks, Inc., a pioneer in the wireless telecommunication industry. He a founder of American Mobile Satellite Company (renamed Motient, then later TerreStar), where he served over 10 years on the Board of Directors, including the Executive, Audit and Compensation Committees, and as a Member of the Executive Committee when it approved the formation and funding of XM Satellite Radio and MSV Ventures.
Over the years Billy Parrott has earned distinction as an award winning movie producer, director and writer, having formed the film production company, Parrott and People. He received the Peabody Award for directing THE BOY KING, a television movie depicting the childhood life of Dr. Martin Luther King, starring Oscar Nominee, Howard Rollins. He Directed and wrote FROM KING TO CONGRESS, an award winning, National television documentary on Andy Young’s successful bid for Congress which premiered at the Kennedy Center , and numerous other documentaries and videos.
Mr. Parrott enlisted in the United States Air Force serving four years prior to entering and graduating from Oregon State University with BS in Business Administration. He attended Oregon State on a football scholarship under legendary Hall of Fame Coach, Tommy Prothro. He still serves several boards including the American Youth Hostel.
Peter Kroll, MD
Dr. Peter Kroll, MD is Board Certified in Anesthesiology and Pain Management. He was a founder and developer of Comprehensive Pain Specialists, a multi-state pain practice in the southeast from 2006 to 2018. Dr. Kroll currently is co-developing with Therapix Medical Solutions in pain patient care and physician services growth. He is directing Therapix Medical Solutions, under Therapix Bioscience, in integrating interventional pain management with novel adjunctive non opioid unique cannabinoid technologies to reduce opioid dependency in treatment algorithms. He also works in the anesthesia and pain management consulting industry. Specializing in the field of Pain Management, Dr. Kroll creates treatment and management plans for patients suffering from chronic pain resulting from a wide range of disorders, diseases, and complications. Throughout his time as a practicing physician, he has directed over 30 clinical trials as a principal and sub investigator, and authored multiple publications.
Dr. Kroll graduated from Loma Linda University School of Medicine in 1997 in the top 10% of his class with academic recognition admission into the Alpha Omega Alpha Society , and through 2001 completed his Surgical Internship, 6 months of Orthopedic residency and 3 years of Anesthesiology residency at Loma Linda University Medical Center. He then completed his Interventional Pain Fellowship at Wake Forest University Baptist Hospital in 2002. In 1993, Dr. Kroll graduated summa cum laude from Southern Adventist University (Collegedale, TN) with a BA in Religion and a Minor in Chemistry.
Albert Röder, PhD
Dr. Albert Röder joined Genelux Corporation in 2004 after retiring from Roche Applied Science as Head of Global R&D and Marketing Support. In February of that year, he was elected to the Board of Directors of Genelux Corporation. His distinguished 33-year career in the pharmaceutical and diagnostics industries included several operative and leadership positions in research and development, manufacturing, marketing, strategy and business development within international cross-functional teams. Before joining Roche, Dr. Röder worked for Boehringer Mannheim, where he rose to Head of Research in Enzymology, Proteinchemistry and Chemistry, then to Head of the Global Product Supply Unit of its Business Unit, Biochemicals. He holds a PhD in organic chemistry from the University of Tübingen in Germany.
Byron Georgiou has had a long career in the private and public sector in business, law and government service. From 2009 to 2011 he served as one of ten bipartisan nationwide members on the Financial Crisis Inquiry Commission, which conducted America’s official inquiry into the causes of the continuing financial, economic and housing crises, and reported its results to the President and Congress. (http://fcic.law.stanford.edu).
Byron currently oversees Georgiou Enterprises, with wide-ranging interests, including as Chair, President, CEO and controlling shareholder of Xtreme Green Electric Vehicles, Inc. (www.xgev.com), manufacturer of lithium- ion, iron-phosphate battery powered all-electric niche vehicles distributed worldwide; lead investor and sole non-founder, independent director from 2010 to 2016 of Health Fusion (www.healthfusion.com), providing practice management and cloud-based healthcare information technology to U.S. healthcare providers, which was sold in 2016 for up to $190 Million to Quality Systems Inc. (QSII-NASDAQ); co-founder in 2005 of and continuing advisor to Corinthian Capital Group (www.corinthiancap.com), a New York and Boston based middle market private equity fund; director since 2014 of Genelux, a clinical stage biopharmaceutical company that has developed a proprietary oncolytic virus based technology platform and deep pipeline of products, www.Genelux.com; director since 2016 of NIPD Genetics, a biotechnology company active in the field of designing, developing, and manufacturing non-invasive genetics tests, www.NIPD.com; former director of Group Aero (www.groupaero.com), which provided advanced engineering, design and manufacturing services to the space, commercial aerospace and defense markets; former director of Mortgage Resolution Partners, a community advisory firm that assisted local governments in addressing the underwater mortgage crisis in America; and over 30 year director and 1985 co-founder with Jack Ford, son of President Gerald Ford, of InfoplaceUSA (www.infoplaceusa.com), providing customer services at regional shopping centers nationwide.
Byron has served since 2005 on the advisory board of the Harvard Law School Program on Corporate Governance (www.law.harvard.edu/programs/corp_gov), which hosts the world’s leading blog on corporate governance and financial regulation. From 2000 to 2011, he was Of Counsel to Robbins, Geller, Rudman & Dowd (www.rgrdlaw.com), and its predecessor law firms, the world’s largest plaintiffs’ securities practice, investigating and civilly prosecuting financial fraud, with leadership roles in the historic litigations on behalf of victimized institutional investors at Enron, WorldCom, Dynegy, AOL/TimeWarner and UnitedHealth.
In 1994, Byron co-founded American Partners Capital Group with Dale Hanson, then CEO of the California Public Employees’ Retirement System (CalPERS), the nation’s largest pension fund, to meet the needs of institutional investors and investment managers with capital formation in a variety of alternative asset categories.
During the second of Jerry Brown’s four terms as California Governor, Byron served as Legal Affairs Secretary, responsible for litigation by and against the Governor, judicial appointments, liaison with the Attorney General, Judiciary and State Bar, legal advice to the Governor and members of his Cabinet, and exercise of the Governor’s powers of extradition and clemency.
Byron attended Stanford University on a full Alfred P. Sloan academic scholarship, graduating with Great Distinction with an A.B. in Political Science, as a participant in the Honors Program in Social Thought and Institutions, and received his J.D. Magna Cum Laude from Harvard Law School.